6 active not recruiting, 3 completed, 3 recruiting, 3 terminated. 11 Phase 2, 8 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 6, Recruiting 3, Completed 1, Terminated 1 |
| Phase 1 | 8 | Completed 3, Recruiting 2, Terminated 2, Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow ALX148: new trials by email Literature Review of ALX148 trials Research Report on ALX148
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer Evorpacept (ALX148), Trastuzumab, Paclitaxel - Breast Cancer, Metastatic | Phase 2 | Recruiting | ALX Oncology Inc. | 120 | 2025-12-10 | 2026-09-25 |
| Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) Evorpacept - Oropharynx Cancer | Phase 2 | Active not recruiting | University of California, San Diego | 28 | 2024-02-23 | 2026-07-16 |
| Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer Pembrolizumab, ALX148, Doxorubicin - Ovarian Cancer | Phase 2 | Active not recruiting | Alexander B Olawaiye, MD | 16 | 2023-03-30 | 2026-07-21 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) Evorpacept, Enfortumab Vedotin - Bladder Cancer, Urothelial Carcinoma | Phase 1 | Completed | ALX Oncology Inc. | 36 | 2022-11-02 | 2025-07-25 |
| Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer Evorpacept (ALX148), Cetuximab, Pembrolizumab - Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | Terminated | University of Colorado, Denver | 19 | 2022-07-28 | 2026-09-03 |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) Evorpacept (ALX148), Trastuzumab, Ramucirumab - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | ALX Oncology Inc. | 127 | 2022-01-15 | 2025-08-07 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer Zanidatamab, Evorpacept - HER2-expressing Cancers | Phase 1 / Phase 2 | Completed | Jazz Pharmaceuticals | 52 | 2021-09-15 | 2026-07-01 |
| Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | ALX Oncology Inc. | 172 | 2021-05-10 | 2025-08-03 |
| A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) evorpacept, venetoclax, azacitidine - Acute Myeloid Leukemia, AML, Adult | Phase 1 | Terminated | ALX Oncology Inc. | 14 | 2021-05-05 | 2024-11-27 |
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) evorpacept, pembrolizumab - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | ALX Oncology Inc. | 189 | 2021-04-02 | 2025-08-01 |
| Isatuximab in Combination With Novel Agents in RRMM - Master Protocol Isatuximab, Dexamethasone, Pomalidomide - Plasma Cell Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | Sanofi | 258 | 2021-01-25 | 2026-10-13 |
| A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) evorpacept, azacitidine - Higher Risk Myelodysplastic Syndromes | Phase 1 | Terminated | ALX Oncology Inc. | 65 | 2020-10-02 | 2025-07-20 |
| A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) Evorpacept (ALX148), Pembrolizumab, Trastuzumab - Metastatic Cancer, Solid Tumor | Phase 1 | Completed | ALX Oncology Inc. | 174 | 2017-02-03 | 2025-08-01 |
Neoplasm Metastasis (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Composite Lymphoma (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm, Residual (1)
ALX Oncology Inc. (8) · Alexander B Olawaiye, MD (1) · Jazz Pharmaceuticals (1) · M.D. Anderson Cancer Center (1) · QuantumLeap Healthcare Collaborative (1) · Sanofi (1) · University of California, San Diego (1) · University of Colorado, Denver (1)
United States (15) · South Korea (7) · Spain (5) · Australia (4) · Singapore (4) · United Kingdom (4) · Belgium (3) · France (3) · Italy (3) · Canada (2) · Netherlands (2) · Czechia (1) · Germany (1) · Greece (1) · Israel (1)
Alexander B Olawaiye, MD (1) · Jospeh A Califano, MD (1) · Paolo Strati, MD (1) · Paula R Pohlmann, MD, MSc, PhD (1) · Wells Messersmith, MD (1)
PMID 33963014, PMID 34793719, PMID 36841672, PMID 39319495, PMID 40207726, PMID 41171165, PMID 42786305
2023 (2)